Snapshot from May 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Eisai
Company

Eisai

Tracked across 4 events · 32 articles · First seen Apr 16, 2026 · Last active May 28, 2026

Sentiment
-8
Attention
6
Events
4
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (4)
4 70
Business
Eisai Projects Leqembi Revenue Growth
Eisai, in collaboration with BioArctic, announced a projected revenue of JPY 143.5 billion (approximately SEK 8.4 billion) for their Alzheimer's drug, Lecanemab, for fiscal year 2026 (April 2026 - March 2027). This represents a 63%…
Impact: Eisai, BioArctic's partner, announced a projected revenue of JPY 143.5 billion for Lecanemab in FY 2026, demonstrating strong sales growth and continued commercialization efforts for the Alzheimer's drug.
May 15, 2026 · 6 articles
6 -80
Tech
Alzheimer's Anti-Amyloid Drugs Ineffective
Impact: Eisai co-produces lecanemab (Leqembi), an anti-amyloid drug whose effectiveness was disputed by the Cochrane review, potentially leading to financial repercussions.
Apr 16, 2026 · 6 articles
4 -20
Regulatory
Leqembi Iqlik PDUFA Date Extended
The United States — Food and Drug Administration has extended the review period for Eisai's supplemental Biologics License Application (sBLA) for Lecanemab Iqlik, a once-weekly subcutaneous injection of lecanemab irmb for early Alzheimer's disease. The…
Impact: Eisai is responsible for the clinical development, marketing authorization applications, and commercialization of Lecanemab. The FDA's extension of the PDUFA date for Lecanemab Iqlik's sBLA directly impacts Eisai's timeline for market expansion.
May 08, 2026 · 13 articles
2 0
Business
BioArctic Q1 2026 Report Presentation
BioArctic will publish its first quarter report for January - March 2026 on May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, BioArctic is inviting investors, analysts, and media to a webcast…
Impact: Eisai is mentioned as a partner with BioArctic in the development of Leqembi.
May 13, 2026 · 7 articles
Key Actions (6)
80 Eisai announced review extension BiogenLeqembi Iqlik PDUFA Date Extended
75 United States — Food and Drug Administration requested additional information EisaiLeqembi Iqlik PDUFA Date Extended
50 United States — Food and Drug Administration accepted application EisaiLeqembi Iqlik PDUFA Date Extended
40 United States — Food and Drug Administration requested additional information EisaiEisai Projects Leqembi...
30 Eisai submitted applicationLeqembi Iqlik PDUFA Date Extended
30 Eisai submitted application JapanEisai Projects Leqembi...
Relationships (2)
BioArctic licensee ↔ Eisai Eisai holds the license to clinically develop and commercialize BioArctic's Alzh
BioArctic licensor ↔ Eisai BioArctic is the original developer and licensor of the Alzheimer's drug Leqembi
NEWSDESK
Track Eisai live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.